Cingulate Inc
Research Cingulate Inc (CING) on Bullrun: market cap USD 67.95M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCING
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 67.95M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 5.87M
- Free cash flow-USD 5.97M
Valuation Snapshot
latest market cap is USD 67.95M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 22.45M | -USD 17.41M | n/a | -4.44 | USD 10.95M | USD 8.79M | USD 2.51M |
| FY2024 | USD 0 | -USD 16.56M | -USD 18.66M | n/a | -10.86 | USD 12.21M | USD 5.10M | USD 7.46M |
| FY2023 | USD 0 | -USD 23.53M | -USD 15.26M | n/a | -311.99 | USD 52.42K | USD 3.51M | -USD 6.87M |
| FY2022 | USD 0 | -USD 17.68M | -USD 16.04M | n/a | -29.35 | USD 5.36M | USD 5.87M | USD 3.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 67.95M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 31.47M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 16.77M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 7.18M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 11.30M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 31.20M | n/a | n/a | n/a |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cingulate Inc's market cap?
Cingulate Inc's market capitalization is USD 67.95M.
What does Cingulate Inc do?
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety.